Division of General Medicine, University of California at Davis, Sacramento2Center for Healthcare Policy and Research, University of California at Davis, Sacramento.
JAMA. 2013 Nov 6;310(17):1818-28. doi: 10.1001/jama.2013.280038.
Encouraging primary care patients to address depression symptoms and care with clinicians could improve outcomes but may also result in unnecessary treatment.
To determine whether a depression engagement video (DEV) or a tailored interactive multimedia computer program (IMCP) improves initial depression care compared with a control without increasing unnecessary antidepressant prescribing.
DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial comparing DEV, IMCP, and control among 925 adult patients treated by 135 primary care clinicians (603 patients with depression and 322 patients without depression, defined by Patient Health Questionnaire-9 [PHQ-9] score) conducted from June 2010 through March 2012 at 7 primary care clinical sites in California.
DEV targeted to sex and income, an IMCP tailored to individual patient characteristics, and a sleep hygiene video (control).
Among depressed patients, superiority assessment of the composite measure of patient-reported antidepressant drug recommendation, mental health referral, or both (primary outcome); depression at 12-week follow-up, measured by the PHQ-8 (secondary outcome). Among nondepressed patients, noninferiority assessment of clinician- and patient-reported antidepressant drug recommendation (primary outcomes) with a noninferiority margin of 3.5%. Analyses were cluster adjusted.
Of the 925 eligible patients, 867 were included in the primary analysis (depressed, 559; nondepressed, 308). Among depressed patients, rates of achieving the primary outcome were 17.5% for DEV, 26% for IMCP, and 16.3% for control (DEV vs control, 1.1 [95% CI, -6.7 to 8.9], P = .79; IMCP vs control, 9.9 [95% CI, 1.6 to 18.2], P = .02). There were no effects on PHQ-8 measured depression score at the 12-week follow-up: DEV vs control, -0.2 (95% CI, -1.2 to 0.8); IMCP vs control, 0.9 (95% CI, -0.1 to 1.9). Among nondepressed patients, clinician-reported antidepressant prescribing in the DEV and IMCP groups was noninferior to control (mean percentage point difference [PPD]: DEV vs control, -2.2 [90% CI, -8.0 to 3.49], P = .0499 for noninferiority; IMCP vs control, -3.3 [90% CI, -9.1 to 2.4], P = .02 for noninferiority); patient-reported antidepressant recommendation did not achieve noninferiority (mean PPD: DEV vs control, 0.9 [90% CI, -4.9 to 6.7], P = .23 for noninferiority; IMCP vs control, 0.3 [90% CI, -5.1 to 5.7], P = .16 for noninferiority).
A tailored IMCP increased clinician recommendations for antidepressant drugs, a mental health referral, or both among depressed patients but had no effect on mental health at the 12-week follow-up. The possibility that the IMCP and DEV increased patient-reported clinician recommendations for an antidepressant drug among nondepressed patients could not be excluded.
clinicaltrials.gov Identifier: NCT01144104.
鼓励初级保健患者与临床医生一起解决抑郁症状和护理问题可以改善结果,但也可能导致不必要的治疗。
确定抑郁参与视频 (DEV) 或量身定制的交互式多媒体计算机程序 (IMCP) 是否比没有增加不必要的抗抑郁药物处方的对照组更能改善初始抑郁护理。
设计、地点和参与者:这是一项随机临床试验,在加利福尼亚州 7 个初级保健临床站点的 135 名初级保健临床医生治疗的 925 名成年患者(603 名抑郁症患者和 322 名无抑郁症患者,定义为 PHQ-9 [患者健康问卷-9] 评分)中比较 DEV、IMCP 和对照组。试验于 2010 年 6 月至 2012 年 3 月进行。
针对性别和收入的 DEV,针对个体患者特征的 IMCP,以及睡眠卫生视频(对照组)。
在抑郁患者中,评估患者报告的抗抑郁药物推荐、心理健康转介或两者的综合衡量标准的优越性(主要结果);使用 PHQ-8 测量 12 周随访时的抑郁(次要结果)。在非抑郁患者中,评估临床医生和患者报告的抗抑郁药物推荐的非劣效性(主要结果),非劣效性边缘为 3.5%。分析进行了聚类调整。
在 925 名合格患者中,有 867 名患者纳入主要分析(抑郁患者 559 名,非抑郁患者 308 名)。在抑郁患者中,DE-V 组达到主要结果的比例为 17.5%,IMCP 组为 26%,对照组为 16.3%(DEV 与对照组相比,1.1 [95%CI,-6.7 至 8.9],P =.79;IMCP 与对照组相比,9.9 [95%CI,1.6 至 18.2],P =.02)。在 12 周随访时,使用 PHQ-8 测量的抑郁评分没有影响:DEV 与对照组相比,-0.2(95%CI,-1.2 至 0.8);IMCP 与对照组相比,0.9(95%CI,-0.1 至 1.9)。在非抑郁患者中,DEV 和 IMCP 组的临床医生报告的抗抑郁药物处方与对照组相比不劣效(平均百分比点差异 [PPD]:DEV 与对照组相比,-2.2 [90%CI,-8.0 至 3.49],P =.0499 用于非劣效性;IMCP 与对照组相比,-3.3 [90%CI,-9.1 至 2.4],P =.02 用于非劣效性);患者报告的抗抑郁药物推荐未达到非劣效性(平均 PPD:DEV 与对照组相比,0.9 [90%CI,-4.9 至 6.7],P =.23 用于非劣效性;IMCP 与对照组相比,0.3 [90%CI,-5.1 至 5.7],P =.16 用于非劣效性)。
量身定制的 IMCP 增加了抑郁患者的临床医生对抗抑郁药物、心理健康转介或两者的推荐,但在 12 周随访时对心理健康没有影响。不能排除 IMCP 和 DEV 会增加非抑郁患者报告的临床医生对抗抑郁药物的推荐的可能性。
clinicaltrials.gov 标识符:NCT01144104。